Determination of systemic exposure and characterization of pharmacokinetics of the tri-functional antibody catumaxomab (anti-EpCAM X anti-CD3) administered intraperitoneally in EpCAM positive cancer p...

Update Il y a 4 ans
Reference: EUCTR2005-001700-39

Determination of systemic exposure and characterization of pharmacokinetics of the tri-functional antibody catumaxomab (anti-EpCAM X anti-CD3) administered intraperitoneally in EpCAM positive cancer patients with malignant ascites

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

- Determination of systemic exposure of catumaxomab during and after four intraperitoneal infusions with increasing doses - Characterization of pharmacokinetics of catumaxomab after the second, the third and the fourth intraperitoneal infusion


Inclusion criteria

  • epithelial cell adhesion molecule (EpCAM) expressing tumors in patients with malignant ascites requiring therapeutic ascites puncture

Links